Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cost-effectiveness of treatment for chronic hepatitis C infection

Newer treatment options for hepatitis C are reasonably cost-effective, but results vary widely across patient subgroups and depend on quality-of-life assumptions, find researchers in this week's issue of the Journal of the American Medical Association.

News image

fiogf49gjkf04

Over 2.5 million people in the United States have chronic hepatitis C virus (HCV) infection.

However, as public health campaigns are pursued, a growing number of treatment candidates are likely to have minimal evidence of liver damage.

In this study, researchers examined the benefits and cost-effectiveness of treatments for chronic hepatitis C infection in asymptomatic, HCV sero-positive, but otherwise healthy individuals.

The team performed a cost-effectiveness analysis using a Markov model of the natural history of HCV infection and impact of treatment.

Probability of developing cirrhosis over a 30-year period was between 13% and 46% for men, and 1% and 29% for women.
Journal of the American Medical Association

They derived natural history parameters from an epidemiologic model. These were empirically calibrated to provide a good fit to observed data on both prevalence of HCV seropositivity and time trends in outcomes.

The researchers assessed cohorts of 40-year-olds who had elevated levels of alanine aminotransferase, positive HCV RNA assays and serologic tests for antibody to HCV. Subjects had no histological evidence of fibrosis on liver biopsy.

The subjects were treated using either standard or pegylated interferon alfa-2b, or combination therapy with standard or pegylated interferon plus ribavirin.

The team evaluated the lifetime costs of treatment, life expectancy, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios.

The researchers found that the probability of patients with chronic HCV developing cirrhosis over a 30-year period was between 13% and 46% for men, and 1% and 29% for women.

They determined that the incremental cost-effectiveness of combination therapy with pegylated interferon for men was between $26,000 and $64,000 per QALY for genotype 1, and between $10,000 and $28,000 for other genotypes.

The cost-effectiveness for women was between $32,000 and $90,000 for genotype 1, and between $12,000 and $42,000 for other genotypes.

The research team found that the benefits of treatment were largely improvements in health-related quality of life, rather than prolonged survivorship, meaning that cost-effectiveness ratios expressed as dollars per year of life were substantially higher.

In addition, results were most sensitive to assumptions about the gains and decrements in health-related quality of life associated with treatment.

Dr Joshua Salomon's team concluded, "While newer treatment options for hepatitis C appear to be reasonably cost-effective on average, these results vary widely across different patient subgroups and depend critically on quality-of-life assumptions".

"As the pool of persons eligible for treatment for HCV infection expands to the more general population, it will be imperative for patients and their physicians to consider these assumptions in making individual-level treatment decisions".

JAMA 2003; 290(2): 228-37
10 July 2003

Go to top of page Email this page Email this page to a colleague

 21 November 2017 
Prepregnancy obesity and maternal mortality
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Sexual functioning in Hep C
 02 November 2017 
Rural residence and risk of IBD
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us